Stensrud P, Sjaastad O
Ups J Med Sci Suppl. 1980;31:37-40.
Atenolol, 50 mg, b.i.d., and propranolol, 80 mg b.i.d.,. were given to 28 patients with a presumed diagnosis of migraine, in a placebo-controlled double-blind cross-over study, where each period lasted 6 weeks. In the total material, atenolol was significantly better than placebo in reducing attacks, whereas propranolol showed no definite such effect. In seven patients the number of headache days was remarkably high (average: 22 headache days in 42 days), which may indicate that they have been inappropriately included in the material or have recorded interparoxysmal headache in addition to attacks. If these patients are excluded, the attack-reducing effect of propranolol and tenormin is significant and of equal magnitude.
在一项安慰剂对照的双盲交叉研究中,对28名初步诊断为偏头痛的患者给予阿替洛尔(50毫克,每日两次)和普萘洛尔(80毫克,每日两次),每个阶段持续6周。在整个研究对象中,阿替洛尔在减少发作方面明显优于安慰剂,而普萘洛尔未显示出明确的此类效果。有7名患者的头痛天数非常多(平均:42天中有22天头痛),这可能表明他们被不恰当地纳入了研究对象,或者除了发作性头痛外还记录了发作间期头痛。如果排除这些患者,普萘洛尔和阿替洛尔减少发作的效果显著且程度相当。